Che-Kai Tsao

Prof. Che-Kai Tsao

Mount Sinai Hospital: New York, NY, US
+1

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Urology
Verified
Journal Article
Closed access
CTChe-Kai Tsao
Che-Kai Tsao
KGKathryn P. Gray
Kathryn P. Gray
MNMari Nakabayashi
Mari Nakabayashi
CECarolyn Evan
Carolyn Evan
PKPhilip W. Kantoff
Philip W. Kantoff
WOWilliam Oh
William Oh
We examined differences in outcome in patients with biopsy Gleason score 8 vs 9-10 who received definitive local therapy. Using an institutional database we identified a cohort of 847 patients with biopsy Gleason 8-10 disease who received definitive local therapy with radiation therapy or radical prostatectomy between January 2001 and December 2011. Multivariable Cox modeling was used to assess the association of Gleason score 8 vs 9-10 with time to biochemical recurrence, metastasis and overall survival, and evaluate treatment by Gleason score interaction. Median followup in the cohort was 5.3 years. Baseline patient characteristics were similar for biopsy Gleason 8 vs 9-10. Gleason 9-10 disease was associated with higher prostate specific antigen at diagnosis. As local treatment such patients were also more likely to have received radiation therapy (58% vs 46%, p = 0.001) and neoadjuvant/adjuvant androgen deprivation therapy (64% vs 49%, p <0.001). Those with higher grade disease were at increased risk for metastasis (HR 1.41, 95% CI 1.11-1.79). There was a trend toward an increased risk of death in Gleason 9-10 vs 8 cases (HR 1.28, 95% CI 0.98-1.66). The increased risk of death for Gleason 9-10 was mainly observed in patients treated with radical prostatectomy with or without additional radiation therapy (HR 1.74, 95% CI 1.15-2.65). Patients with localized biopsy Gleason 9-10 disease treated with definitive local therapy had worse outcomes than those diagnosed with biopsy Gleason 8 disease. Clinical trials are urgently needed that incorporate newer approaches to Gleason 9-10 cancer.

20 July 2021 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
MAMaddison Archer
Maddison Archer
Navneet DograNavneet Dogra
Navneet Dogra
ZDZ. Dovey
Z. Dovey
TGT. Ganta
T. Ganta
HJH.-S. Jang
H.-S. Jang
Natasha KyprianouNatasha Kyprianou
Natasha Kyprianou
The urinary tract is highly innervated by autonomic nerves which are essential in urinary tract development, the production of growth factors, and the control of homeostasis. These neural signals may become dysregulated in several genitourinary (GU) disease states, both benign and malignant. Accordingly, the autonomic nervous system is a therapeutic target for several genitourinary pathologies including cancer, voiding dysfunction, and obstructing nephrolithiasis. Adrenergic receptors (adrenoceptors) are G-Protein coupled-receptors that are distributed throughout the body. The major function of α1-adrenoceptors is signaling smooth muscle contractions through GPCR and intracellular calcium influx. Pharmacologic intervention of α-and β-adrenoceptors is routinely and successfully implemented in the treatment of benign urologic illnesses, through the use of α-adrenoceptor antagonists. Furthermore, cell-based evidence recently established the antitumor effect of α1-adrenoceptor antagonists in prostate, bladder and renal tumors by reducing neovascularity and impairing growth within the tumor microenvironment via regulation of the phenotypic epithelial-mesenchymal transition (EMT). There has been a significant focus on repurposing the routinely used, Food and Drug Administration-approved α1-adrenoceptor antagonists to inhibit GU tumor growth and angiogenesis in patients with advanced prostate, bladder, and renal cancer. In this review we discuss the current evidence on (a) the signaling events of the autonomic nervous system mediated by its cognate α- and β-adrenoceptors in regulating the phenotypic landscape (EMT) of genitourinary organs; and (b) the therapeutic significance of targeting this signaling pathway in benign and malignant urologic disease.

30 December 2013 in Cancer
Verified
Journal Article
Closed access
PDF file
SDStephanie M. Doctor
Stephanie M. Doctor
CTChe-Kai Tsao
Che-Kai Tsao
JGJames H. Godbold
James H. Godbold
MGMatthew D. Galsky
Matthew D. Galsky
WOWilliam Oh
William Oh

19 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
JAJonathan Anker
Jonathan Anker
Justin MillerJustin Miller
Justin Miller
NTNicole Taylor
Nicole Taylor
Natasha KyprianouNatasha Kyprianou
Natasha Kyprianou
CTChe-Kai Tsao
Che-Kai Tsao
Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subset of patients, many combination-based approaches have led to improved outcomes. The success of such approaches is a direct result of the tumor immunology knowledge accrued regarding the RCC microenvironment, which, while highly immunogenic, demonstrates many unique characteristics. Ongoing translational work has elucidated some of the mechanisms of response, as well as primary and secondary resistance, to immunotherapy. Here, we provide a comprehensive review of the RCC immunophenotype with a specific focus on how preclinical and clinical data are shaping the future of immunotherapy.

1 November 2016 in European Urology
Verified
Journal Article
Closed access
CTChe-Kai Tsao
Che-Kai Tsao
MGMatthew D. Galsky
Matthew D. Galsky
WOWilliam Oh
William Oh

Verified
Journal Article
Open access
PDF file
TCTzu-Yi Chen
Tzu-Yi Chen
MMMeredith Mihalopoulos
Meredith Mihalopoulos
LZLaura Zuluaga
Laura Zuluaga
JRJordan Rich
Jordan Rich
TGTeja Ganta
Teja Ganta
Natasha KyprianouNatasha Kyprianou
Natasha Kyprianou
Extracellular vesicles (EVs)—including apoptotic bodies, microvesicles, and exosomes—are released by almost all cell types and contain molecular footprints from their cell of origin, including lipids, proteins, metabolites, RNA, and DNA. They have been successfully isolated from blood, urine, semen, and other body fluids. In this review, we discuss the current understanding of the predictive value of EVs in prostate and renal cancer. We also describe the findings supporting the use of EVs from liquid biopsies in stratifying high-risk prostate/kidney cancer and advanced disease, such as castration-resistant (CRPC) and neuroendocrine prostate cancer (NEPC) as well as metastatic renal cell carcinoma (RCC). Assays based on EVs isolated from urine and blood have the potential to serve as highly sensitive diagnostic studies as well as predictive measures of tumor recurrence in patients with prostate and renal cancers. Overall, we discuss the biogenesis, isolation, liquid-biopsy, and therapeutic applications of EVs in CRPC, NEPC, and RCC.